Overview
On 2 September 2004, orphan designation (EU/3/04/220) was granted by the European Commission to Oncoscience AG, Germany, for anti epidermal growth factor receptor antibody h-R3 (cimazumab) for the treatment of glioma.
The sponsorship was transferred to Oncoscience GmbH, Germany, in September 2018.
Key facts
| Active substance |
Anti epidermal growth factor receptor antibody h-R3
|
| Intended use |
Treatment of glioma
|
| Orphan designation status |
Positive
|
| EU designation number |
EU/3/04/220
|
| Date of designation |
02/09/2004
|
| Sponsor |
Oncoscience GmbH |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: